Related Experiment Video

Updated: Feb 1, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.6K

FLT3 inhibitors in acute myeloid leukemia

Mei Wu1, Chuntuan Li2, Xiongpeng Zhu3

  • 1Department of Hematology, The People's Hospital of Bozhou, Bozhou, 236800, China.

Journal of Hematology & Oncology
|December 6, 2018
PubMed

Insights

FLT3 inhibitors are crucial for treating acute myeloid leukemia (AML) with FLT3 mutations. New FLT3 inhibitors and combination therapies show promise in overcoming resistance to existing treatments.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • FMS-like tyrosine kinase 3 (FLT3) mutations are common in acute myeloid leukemia (AML).
  • FLT3 inhibitors represent a significant therapeutic advancement for AML treatment.
  • Midostaurin is the first approved FLT3 inhibitor for FLT3-mutated AML.

Purpose of the Study:

  • To review preclinical and clinical studies of FLT3 inhibitors in AML.
  • To summarize the development and efficacy of various FLT3 inhibitors.
  • To explore strategies for overcoming resistance to FLT3-targeted therapies.

Main Methods:

  • Comprehensive literature review of preclinical and clinical studies.
  • Analysis of data on FLT3 inhibitors including sorafenib, lestaurtinib, sunitinib, tandutinib, quizartinib, midostaurin, gilteritinib, crenolanib, cabozantinib, Sel24-B489, G-749, AMG 925, TTT-3002, and FF-10101.
  • Evaluation of emerging combination therapies.

Main Results:

  • Numerous FLT3 inhibitors are under active clinical investigation.
  • First-generation FLT3 inhibitors like midostaurin have demonstrated clinical utility.
  • Newer generation inhibitors and combination approaches are being developed to address treatment resistance.

Conclusions:

  • FLT3 inhibitors are a critical component of AML therapy.
  • Ongoing research focuses on developing more effective FLT3 inhibitors and combination strategies.
  • Next-generation FLT3 inhibitors and combination therapies hold potential to improve outcomes in FLT3-mutated AML.
Keywords:
Acute myeloid leukemiaFLT3FMS-like tyrosine kinase 3 inhibitorsMidostaurin

More Related Videos

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

2.5K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.7K

Related Concept Videos

Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.0K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
670
Acute Pharyngitis01:30

Acute Pharyngitis

Introduction
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
4.2K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.5K
Acute Pancreatitis I: Introduction01:27

Acute Pancreatitis I: Introduction

Pancreatitis is inflammation of the pancreas, an organ located behind the stomach. It can be either acute or chronic.
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
1.2K